Multicentric Phase II-III study evaluating the tailored management of locally-advanced rectal carcinoma after a favorable response to Induction chemotherapy
Latest Information Update: 06 Nov 2024
Price :
$35 *
At a glance
- Drugs Capecitabine (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Adenocarcinoma; Carcinoma; Rectal cancer
- Focus Therapeutic Use
- Acronyms GRECCAR14
- 30 Sep 2022 Planned number of patients changed from 430 to 1075.
- 12 Oct 2021 New trial record